2-(2-acetamido-3-hydroxyphenoxy)benzoic acid | 1221230-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-acetamido-3-hydroxyphenoxy)benzoic acid
• CAS: 1221230-63-2
• 化学式: C₁₅H₁₃NO₅
• 分子量: 287.272
• InChiKey: KPDJMMKAGQCWOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-acetamido-3-hydroxyphenoxy)benzoic acid 、 氯甲酸乙酯 在 N-甲基吗啉 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  [EN] NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN
  [FR] NOUVEAUX INHIBITEURS POUR TRAITER DES MALADIES ASSOCIÉES À UN TRANSPORT EXCESSIF DE HYALURONANE

  摘要：

  公开号：

  WO2010066909A3
• 作为产物：
  描述：

  2-(2-Amino-3-hydroxyphenoxy)benzoic acid 、 乙酸酐 以 甲醇 为溶剂， 反应 0.5h， 生成 2-(2-acetamido-3-hydroxyphenoxy)benzoic acid
  参考文献：
  名称：

  [EN] NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN
  [FR] NOUVEAUX INHIBITEURS POUR TRAITER DES MALADIES ASSOCIÉES À UN TRANSPORT EXCESSIF DE HYALURONANE

  摘要：

  公开号：

  WO2010066909A3

文献信息

• COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING
  申请人：Universitätsklinikum Münster

  公开号：EP2376429A2

  公开（公告）日：2011-10-19
• NEW ACTIVATORS FOR TREATING AND/OR PREVENTING DISEASES OR MEDICAL CONDITIONS WHICH BENEFIT FROM AN INCREASED TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER
  申请人：Prehm Peter

  公开号：US20110245192A1

  公开（公告）日：2011-10-06

  The present invention relates in general to a compound (activator) which is characterized by a formula selected from the following formulas A, B and/or C or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the activator(s) of the invention and to their use in the treatment of (for treating) and/or preventing diseases or medical conditions which benefit from an increased transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the activator defined herein in a pharmaceutically acceptable form.
• [EN] COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING<br/>[FR] COMPOSÉS AYANT UNE ACTIVITÉ DE CORRECTION DU TRAITEMENT CELLULAIRE DU CFTR MUTANT
  申请人：UNIVERSITAETSKLINIKUM MUENSTER

  公开号：WO2010066912A2

  公开（公告）日：2010-06-17

  The present invention relates to a compound which is characterized by the formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof, wherein the ring systems A and B are independently selected from a monosaccharide, aryl (preferably phenyl), a heteroaryl or cycloalkyl (preferably cyclohexan), preferably with all substituents in equatorial configurations; R1 is independently selected from alkyl (preferably C1 to C6), a substituted or unsubstituted phenyl, preferably CH3; R2 is H, alkyl (preferably C1 to C6), a carbohydrate in a glycosidic β-linkage, preferably H; R3, R4, R5, and R6 are independently selected from H, (OH) hydroxy, alkyl preferably C1 to C6, alkoxy (preferably C1 to C6), amino, alkylamino (preferably C1 to C6), halogen, benzylamino, or benzoylamino; X is O, NH, alkylamino (NR), CO, S; and Y is O, NH, alkylamino (NR), CO, S. The present invention also relates to the compound of the invention and, optionally, a pharmaceutically acceptable carrier, for use in the treatment of (for treating) and/or preventing a disease or medical condition which is associated with mutant CFTR.
• [EN] NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN<br/>[FR] NOUVEAUX INHIBITEURS POUR TRAITER DES MALADIES ASSOCIÉES À UN TRANSPORT EXCESSIF DE HYALURONANE
  申请人：UNIVERSITAETSKLINIKUM MUENSTER

  公开号：WO2010066909A3

  公开（公告）日：2010-08-05